ES2160171T3 - Forma purificada de estreptograminas, su preparacion y las composiciones farmaceuticas que la contienen. - Google Patents

Forma purificada de estreptograminas, su preparacion y las composiciones farmaceuticas que la contienen.

Info

Publication number
ES2160171T3
ES2160171T3 ES95926996T ES95926996T ES2160171T3 ES 2160171 T3 ES2160171 T3 ES 2160171T3 ES 95926996 T ES95926996 T ES 95926996T ES 95926996 T ES95926996 T ES 95926996T ES 2160171 T3 ES2160171 T3 ES 2160171T3
Authority
ES
Spain
Prior art keywords
alkyl
dialkylamino
alkylamino
halogen
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926996T
Other languages
English (en)
Inventor
Pascal Anger
Jean-Claude Barriere
Bertrand Bonnavaud
Patrick Lefevre
Jean-Marc Paris
Denis Thibaut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160171(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2160171T3 publication Critical patent/ES2160171T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06182—Dipeptides with the first amino acid being heterocyclic and Pristinamycin II; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

FORMA PURIFICADA DE ESTREPTOGRAMINAS CARACTERIZADA PORQUE COMPRENDE AL MENOS UN COMPONENTE DEL GRUPO B DE LAS ESTREPTOGRAMINAS DE FORMULA GENERAL (I) EN LA QUE R{SUB,1} ES M O ET, R{SUB,2} ES H O OH, Y R{SUB,3} ES UN BENCILO SUSTITUIDO DE FORMULA GENERAL (III) PARA LO CUAL 1) SI R{SUB,2} ES H, R ES NR{SUB,4}R{SUB,5} PARA LO CUAL R{SUB,4} Y R{SUB,5} SON UNO H O UN RADICAL ME Y EL OTRO ME Y R'' ES CL O BR, O R ES ALQUENIL (3 A 5C) SI R{SUB,4} Y R{SUB,5} SON ME, O BIEN 2) R ES H Y R'' ES HALOGENO , ALQUILAMINO O DIALQUILAMINO,UN RESTO ETER-OXIDO, ALQUILTIO, ALQUILO (1 A 3C) O TRIHALOGENOMETILO, O R ES HALOGENO, ALQUILAMINO (2 A 4C), DIALQUILAMINO (2 A 4C) O METIL ETIL AMIO, PIRROLIDINO, ALQUENILALCOILALIMO, DIALQUENILAMINO, UN RADICAL ALQUILCICLOALCOILMETILAMINO, O BIEN UN RESTO ETER-OXIDO, ALQUILTIO, ALQUILTIOMETILO, ALOILO (1 A 6C), ARILO IO TRIHALOGENOMETILO, Y R'' ES H O BIEN R ES HALOGENO, AMINO, ALQUILAMINO O DIALQUILAMINO, UN RESTO ETER-OCIDO, UN RADICAL ALQUILTIO, ALQUILO (1 A 6C) O TRIHALOGENOMETILO Y R'' ES HALOGENO, ALQUILAMINO O DIALQUILAMINO, UN RESTO ETER-OXIDO O ALCAILTIO, LACOILO (1 A 3C), COCRISTALIZADO CON AL MENOS UN COMPONENTE "MINORITARIA" DEL GRUPO A DE FORMULA GENERAL (II) EN LA QUE R" ES H, ME O ET.
ES95926996T 1994-08-02 1995-07-31 Forma purificada de estreptograminas, su preparacion y las composiciones farmaceuticas que la contienen. Expired - Lifetime ES2160171T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9409564A FR2723373B1 (fr) 1994-08-02 1994-08-02 Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
ES2160171T3 true ES2160171T3 (es) 2001-11-01

Family

ID=9465984

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926996T Expired - Lifetime ES2160171T3 (es) 1994-08-02 1995-07-31 Forma purificada de estreptograminas, su preparacion y las composiciones farmaceuticas que la contienen.

Country Status (13)

Country Link
US (1) US6384014B1 (es)
EP (1) EP0773956B1 (es)
JP (1) JPH10503511A (es)
AT (1) ATE202784T1 (es)
AU (1) AU3117495A (es)
CA (1) CA2196450A1 (es)
DE (1) DE69521615T2 (es)
DK (1) DK0773956T3 (es)
ES (1) ES2160171T3 (es)
FR (1) FR2723373B1 (es)
GR (1) GR3036173T3 (es)
PT (1) PT773956E (es)
WO (1) WO1996004298A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416792B1 (en) * 1997-12-24 2002-07-09 Teresa J. Ingram Compositions comprising equisetum and symphytum and methods for the treatment of symptoms associated with mycoplasma infection
FR2775288B1 (fr) * 1998-02-26 2000-03-31 Rhone Poulenc Rorer Sa Derives de streptogramines, leur preparation et les compositons qui les contiennent
DE60006130D1 (de) * 1999-07-27 2003-11-27 Aventis Pharma Sa Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen
FR2796950B1 (fr) * 1999-07-27 2001-09-21 Aventis Pharma Sa Derives de streptogramines, leur preparation et les compositions qui les contiennent
IL164703A0 (en) 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2007092475A2 (en) 2006-02-06 2007-08-16 Franklin And Marshall College Site-specific incorporation of fluorinated amino acids into proteins
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
CN104744476B (zh) 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并吡嗪syk抑制剂
CN104059073B (zh) 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并哌嗪syk抑制剂
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
SI3027171T1 (sl) 2013-07-30 2020-08-31 Gilead Connecticut, Inc. Formulacija inhibitorjev SYK
ES2822285T3 (es) 2013-07-30 2021-04-30 Kronos Bio Inc Polimorfo de inhibidores de SYK
KR20180002888A (ko) 2013-12-04 2018-01-08 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
BR112016028641A2 (pt) 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549062B1 (fr) 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2549063B1 (fr) 1983-07-13 1985-10-25 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2576022B1 (fr) 1985-01-11 1987-09-11 Rhone Poulenc Sante Nouveaux derives de la pristinamycine ii b, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2599036B1 (fr) 1986-05-22 1988-09-09 Rhone Poulenc Sante Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2619008B1 (fr) 1987-08-03 1990-06-29 Cird Utilisation de synergistines dans des compositions pharmaceutiques ou cosmetiques anti-acneiques
FR2674539B1 (fr) * 1991-03-28 1993-05-21 Rhone Poulenc Rorer Sa Procede de preparation enzymatique de macrolactone.
FR2696189B1 (fr) 1992-09-25 1994-11-10 Rhone Poulenc Rorer Sa Polypeptides impliqués dans la biosynthèse des streptogramines, séquences nucléotidiques codant pour ces polypeptides et leur utilisation.
IL121821A (en) 1993-02-17 2000-02-17 Rhone Poulenc Rorer Sa Process for purifying a group A minority component of streptogramin some such purified components and their uses
FR2701709B1 (fr) 1993-02-17 1995-04-07 Rhone Poulenc Rorer Sa Forme purifiée de streptograminés, sa préparation et les compositions pharmaceutiques qui la contiennent.

Also Published As

Publication number Publication date
ATE202784T1 (de) 2001-07-15
EP0773956A1 (fr) 1997-05-21
FR2723373B1 (fr) 1996-09-13
FR2723373A1 (fr) 1996-02-09
CA2196450A1 (fr) 1996-02-15
DK0773956T3 (da) 2001-09-24
EP0773956B1 (fr) 2001-07-04
AU3117495A (en) 1996-03-04
US6384014B1 (en) 2002-05-07
JPH10503511A (ja) 1998-03-31
PT773956E (pt) 2001-11-30
WO1996004298A1 (fr) 1996-02-15
GR3036173T3 (en) 2001-10-31
DE69521615D1 (de) 2001-08-09
DE69521615T2 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
ES2160171T3 (es) Forma purificada de estreptograminas, su preparacion y las composiciones farmaceuticas que la contienen.
DE69303166D1 (de) Klebstoffabweisende silikonzusammensetzungen
ES2128519T3 (es) Nuevas pirido-tiadiazinas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
DE69604114T2 (de) Gemische von photoaktiven Zusammensetzungen enthaltendes Fotoresist
FI963169A0 (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
DE69130283D1 (de) Farbtonerzusammensetzungen
ES2010853A6 (es) Composiciones de tensoactivos sinergicos.
IE812974L (en) Tri-,tetra- and penta peptides
MX9300433A (es) Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
DE69622907T2 (de) Verfahren zur Herstellung von RTV-Einkomponenten-Silicon-Zusammensetzungen
FI930962A (fi) Anordning foer registrering av den malbara laddningens maengd i ett visst oegonblick i en malningstrumma
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2111871T3 (es) Nuevos derivados de aminoacidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
BR9303623A (pt) Composiçoes curáveis de ácido latente
DE69418364D1 (de) Verfahren zur Herstellung von Polybutadienzusammensetzungen
IT1290797B1 (it) Composizioni farmaceutiche stabilizzate
IT1270905B (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
IL97148A0 (en) Oxetanones,their manufacture and pharmaceutical compositions containing them
DK0623620T3 (da) 5-HT3-pyrrolopyrazinderivater
ES2091570T3 (es) Nuevos derivados peptidicos antagonistas de la bradiquidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE69600933D1 (de) Verfahren zur Herstellung von photographischen Elementen enthaltend beladene Latexzusammensetzungen
DE69623464D1 (de) Modifizierte kojibioside analoge
BR9307182A (pt) Composições farmacêuticas de 2-oxindol-1-carboxamidas 3-substituídas
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 773956

Country of ref document: ES